TransCode Therapeutics Welcomes Dr. Anna Moore as Chair of Scientific Advisory Board and Partners with MSU

TransCode Therapeutics Appoints Dr. Anna Moore

In an exciting development for TransCode Therapeutics (NASDAQ: RNAZ), the Boston-based clinical stage company specializing in RNA and immuno-oncology treatments, Dr. Anna Moore has been named the Chair of the Scientific Advisory Board. This pivotal appointment comes alongside a sponsored research agreement with Michigan State University (MSU), signaling the company's dedication to advancing its innovative pipeline targeting high-risk and advanced cancers.

Dr. Anna Moore: A Leader in Cancer Therapeutics

Dr. Moore is not just an exceptional scientist; she is also a co-founder of TransCode, recognized widely for her expertise in molecular imaging and RNA-targeted cancer therapies. Serving as the Associate Dean for Research Development and Director of the Precision Health Program at MSU, Dr. Moore has laid foundational strategies for TransCode’s RNA platform development, particularly for its flagship therapeutic candidate, TTX-MC138. This groundbreaking treatment aims to target microRNA-10b, which has a significant role in cancer metastasis.

Before her tenure at MSU, she amassed an impressive 26 years at the Massachusetts General Hospital and Harvard Medical School, where she held crucial roles, including Professor of Radiology and Director of the Molecular Imaging Laboratory. Her wealth of experience is a tremendous asset to TransCode as it strives to bring innovative RNA-based therapies to market.

Dr. Moore expressed her enthusiasm for this new role, stating, "I am honored and very much looking forward to assuming this role and continuing to collaborate with the TransCode team in advancing innovative RNA-based therapeutics targeting advanced metastatic disease, which remains one of the most significant unmet needs in oncology." This clearly underscores her commitment to improving patient outcomes through cutting-edge research and development.

The Sponsored Research Agreement with Michigan State University

The collaboration with MSU extends beyond Dr. Moore's appointment. TransCode has established a sponsored research agreement designed to propel the company's therapeutic candidates, especially TTX-MC138, from laboratory studies to clinical development. Research at MSU will specifically examine TTX-MC138 in conjunction with Seviprotimut-L, focusing on potential synergies and the efficacy of combined treatment approaches. This agreement aligns with TransCode's strategy to integrate academic research with clinical application, thus accelerating the timeline for innovative cancer therapies.

Seviprotimut-L was acquired through TransCode's acquisition of Polynoma, LLC, presenting new opportunities for the company to explore the combined therapeutic landscape. By leveraging the expertise at MSU, TransCode aims to fast-track the development of its pipeline candidates and refine its treatment approaches for metastatic cancers.

A Promising Future for TransCode Therapeutics

TransCode's focus revolves around pioneering solutions in the field of immuno-oncology and RNA therapeutics. With TTX-MC138 targeting tumors that overexpress the microRNA-10b biomarker, the company is at the forefront of a significant shift towards personalized cancer therapies. The scientific insights provided by Dr. Moore, coupled with collaborative efforts with MSU, are poised to enhance the depth and breadth of the company's research and development efforts.

The road ahead is filled with potential for TransCode Therapeutics as they harness the power of RNA technology to meet critical healthcare needs. The enthusiastic support from leading experts like Dr. Moore and strategic partnerships will undoubtedly play a vital role in shaping the future of cancer treatment. As the oncology field evolves, TransCode remains committed to leading innovation and transforming therapeutic landscape for patients battling cancer.

For more details about TransCode Therapeutics and its innovative pipelines, visit www.transcodetherapeutics.com.